Antioxidant enzyme polymorphisms and neuropsychological outcomes in medulloblastoma survivors: A report from the Childhood Cancer Survivor Study

Neuro-Oncology

Volumn 14, Issue 8, 2012, Pages 1018-1025

  Brackett, Julienne ^a   Krull, Kevin R ^b   Scheurer, Michael E ^a   Liu, Wei ^b   Srivastava, Deo Kumar ^b   Stovall, Marilyn ^c   Merchant, Thomas E ^b   Packer, Roger J ^d   Robison, Leslie L ^b   Okcu, M Fatih ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Childhood Cancer Survivor Study; glutathione S transferase polymorphisms; medulloblastoma; neuropsychological impairment; radiation therapy

Indexed keywords

CELL DNA; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MANGANESE SUPEROXIDE DISMUTASE;

ADULT; AGE; ANXIETY; ARTICLE; BRIEF SYMPTOM INVENTORY; BRIEF SYMPTOM INVENTORY 18; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISTRESS SYNDROME; EMOTIONALITY; FEMALE; GENE DELETION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HOMOZYGOTE; HOSPITALIZED CHILD; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MENTAL DISEASE; NEUROCOGNITIVE QUESTIONNAIRE; NULL ALLELE; PROTEIN FUNCTION; RADIATION DOSE; RATING SCALE; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SCORING SYSTEM; SEX DIFFERENCE; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURED QUESTIONNAIRE;

ADOLESCENT; ADULT; ANTIOXIDANTS; CEREBELLAR NEOPLASMS; CHILD; CRANIAL IRRADIATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MEDULLOBLASTOMA; MENTAL DISORDERS; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; SUPEROXIDE DISMUTASE; SURVIVORS; YOUNG ADULT;

EID: 84864685795     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos123     Document Type: Article

References (47)

1. Packer RJ, Rorke-Adams LB, Lau C, et al. Embryonal and Pineal Region Tumors. In: Pizzo, PA, Poplack, D, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: LippincottWilliams andWilkins; 2011:772-808.
2. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7:813-820.
3. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202-4208.
4. Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist. 2004;10:293-310.
5. Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol. 2004;5:399-408.
6. Palmer SL, Reddick WE, Gajjar A. Understanding the cognitive impact on children who are treated for medulloblastoma. J Pediatr Psychol. 2007;32:1040-1049.
7. Mulhern RK, Palmer SL, Merchant TE, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005;23:5511-5519.
8. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: A Children's Cancer Group study. J Clin Oncol. 2001;19:3470-3476.
9. Palmer SL, Gajjar A, Reddick WE, et al. Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology. 2003;17:548-555.
10. Zebrack BJ, Gurney JG, Oeffinger K, et al. Psychological outcomes in long-term survivors of childhood brain cancer: A report from the childhood cancer survivor study. J Clin Oncol. 2004;22:999-1006.
11. Pang JW, Friedman DL, Whitton JA, et al. Employment status among adult survivors in the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2008;50:104-110.
12. Ellenberg L, Liu Q, Gioia G, et al. Neurocognitive status in long-term survivors of childhood CNS malignancies: A report from the Childhood Cancer Survivor Study. Neuropsychology. 2009;23:705-717.
13. Kunin-Batson A, Kadan-Lottick N, Zhu L, et al. Predictors of independent living status in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2011;57:1197-1203.
14. Janson C, LeisenringW, Cox C, et al. Predictors of marriage and divorce in adult survivors of childhood cancers: A report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2009;18:2626-2635.
15. Kirchhoff AC, Krull KR, Ness KK, et al. Occupational outcomes of adult childhood cancer survivors: A report from the childhood cancer survivor study. Cancer. 2011;117:3033-3044.
16. Robbins ME, Zhao W. Chronic oxidative stress and radiation-induced late normal tissue injury: A review. Int J Radiat Biol. 2004;80:251-259.
17. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160:1-40.
18. Sutton A, Khoury H, Prip-Buus C, et al. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics. 2003;13:145-157.
19. Rosenblum JS, Gilula NB, Lerner RA. On signal sequence polymorphisms and diseases of distribution. Proc Natl Acad Sci USA. 1996;93:4471-4473.
20. Hu YJ, Diamond AM. Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res. 2003;63:3347-3351.
21. Ravn-Haren G, Olsen A, Tjonneland A, et al. Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study. Carcinogenesis. 2006;27:820-825.
22. ZhaoW, Diz DI, Robbins ME. Oxidative damage pathways in relation to normal tissue injury. Br J Radiol. 2007;80 Spec No 1:S23-S31.
23. McIlwainCC, TownsendDM,TewKD. Glutathione S-transferase polymorphisms: Cancer incidence and therapy. Oncogene. 2006;25:1639-1648.
24. Ho AY, Atencio DP, Peters S, et al. Genetic predictors of adverse radiotherapy effects: The Gene-PARE project. Int J Radiat Oncol Biol Phys. 2006;65:646-655.
25. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;3:276-285.
26. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of fulllength cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem. 1997;272:10004-10012.
27. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: A multi-institutional collaborative project. Med Pediatr Oncol. 2002;38:229-239.
28. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: A National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol. 2009;27:2308-2318.
29. Packer RJ, Gurney JG, Punyko JA, et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: Childhood cancer survivor study. J Clin Oncol. 2003;21:3255-3261.
30. Mertens AC, Mitby PA, Radloff G, et al. XRCC1 and glutathione-S- transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. Cancer. 2004;101:1463-1472.
31. Ness KK, Li C, Mitby PA, et al. Characteristics of responders to a request for a buccal cell specimen among survivors of childhood cancer and their siblings. Pediatr Blood Cancer. 2010;55:165-170.
32. Arand M, Muhlbauer R, Hengstler J, et al. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem. 1996;236:184-186.
33. Krull KR, Gioia G, Ness KK, et al. Reliability and validity of the Childhood Cancer Survivor Study Neurocognitive Questionnaire. Cancer. 2008;113:2188-2197.
34. Armstrong GT, Jain N, Liu W, et al. Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies. Neuro Oncol. 2010;12:1173-1186.
35. Derogatis LR. The Brief Symptom Inventory-18 (BSI-18): Administration, scoring and procedures manual. Minneapolis, MN: National Computer Systems; 2000.
36. Barahmani N, Carpentieri S, Li XN, et al. Glutathione S-Transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro Oncol. 2009;11: 292-300.
37. Small BJ, Rawson KS, Walsh E, et al. Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer. 2011;117:1369-1376.
38. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30:445-600.
39. Dirven HA, van Ommen B, van Bladeren PJ. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res. 1994;54:6215-6220.
40. Goto S, Iida T, Cho S, et al. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res. 1999;31:549-558.
41. Smith MT, Evans CG, Doane-Setzer P, et al. Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res. 1989;49:2621-2625.
42. Weber GF, Waxman DJ. Denitrosation of the anti-cancer drug 1,3-bis(2-chloroethyl)-1- nitrosourea catalyzed by microsomal glutathione S-transferase and cytochrome P450 monooxygenases. Arch Biochem Biophys. 1993;307:369-378.
43. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001;10:1239-1248.
44. Harada S, Fujii C, Hayashi A, Ohkoshi N. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun. 2001;288:887-892.
45. Santt O, Baranova H, Albuisson E, Bignon YJ, Lucotte G. Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson's disease. Eur J Neurol. 2004;11:247-251.
46. Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J. 1997;324(Pt 1):25-28.
47. Ishii J, Natsume A, Wakabayashi T, et al. The free-radical scavenger edaravone restores the differentiation of human neural precursor cells after radiation-induced oxidative stress. Neurosci Lett. 2007;423: 225-230.